Rehmann Capital Advisory Group’s Core Laboratories CLB Stock Holding History

Rehmann Capital Advisory Group’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	$4.33K	Sell	93 -15	-14%	-$697	﹤0.01%	1244
2019 Q2	$5.65K	Sell	108 -64	-37%	-$3.75K	﹤0.01%	1525
2019 Q1	$11.9K	Buy	172 +1	+0.6%	+$67	﹤0.01%	1279
2018 Q4	$10.3K	Sell	171 -118	-41%	-$10.2K	﹤0.01%	1044
2018 Q3	$33.6K	Sell	289 -57	-16%	-$6.43K	﹤0.01%	946
2018 Q2	$43.7K	Sell	346 -433	-56%	-$52.7K	0.01%	827
2018 Q1	$84K	Buy	+779	New	+$86.2K	0.01%	589

Other funds holding CLB

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return

VanEck Associates New York $164B AUM 112.45% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $32.2B AUM 10.98% 1-Year Est. Return

Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Rehmann Capital Advisory Group's CLB Position: Q3 2019 in Review

Rehmann Capital Advisory Group reduced its Core Laboratories (CLB) stake by 14% in Q3 2019, selling an estimated $697 and leaving 93 shares worth $4.33K. The position accounts for ﹤0.01% of the portfolio, ranked #1244.

Rehmann Capital Advisory Group first reported a position in CLB in Q1 2018 and has held it in 7 quarters since. The position peaked at $84K in Q1 2018. 274 funds tracked by Wall St. Rank hold CLB as of Q3 2019.

Rehmann Capital Advisory Group held 93 shares of Core Laboratories worth $4.33K as of Q3 2019.
Rehmann Capital Advisory Group sold 15 Core Laboratories shares in Q3 2019, an estimated $697.
Core Laboratories made up ﹤0.01% of Rehmann Capital Advisory Group's portfolio in Q3 2019, its #1244 holding.
Rehmann Capital Advisory Group first reported a position in Core Laboratories in Q1 2018 and has held it in 7 quarters since.
Rehmann Capital Advisory Group's Core Laboratories position peaked at $84K in Q1 2018.
274 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2019.

Based on Rehmann Capital Advisory Group's 13F filing for Q3 2019, filed 2 Jan 2020.